Kairos Pharma: Potential To Remove Resistance With Established Drugs
Portfolio Pulse from
Kairos Pharma's ENV-105 targets CD105 proteins to enhance the efficacy of existing cancer therapies like ERLEADA and TAGRISSO. The company aims to overcome resistance in CRPC and EGFR-mutant NSCLC, with key data expected in 2025. Kairos may need to raise funds by early 2025.
December 26, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kairos Pharma's ENV-105 could enhance the efficacy of TAGRISSO, a drug by AstraZeneca, by targeting CD105 proteins to restore sensitivity in cancer cells.
ENV-105 aims to enhance TAGRISSO's efficacy, potentially increasing its market value and sales for AZN if successful.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Kairos Pharma's ENV-105 could enhance the efficacy of ERLEADA, a drug by Johnson & Johnson, by targeting CD105 proteins to restore sensitivity in cancer cells.
ENV-105 aims to enhance ERLEADA's efficacy, potentially increasing its market value and sales for JNJ if successful.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50